Rigel Pharmaceuticals opened lower at $44.21, compared with its previous close of $44.52. In the last trading session, the stock traded between $43.44 and $46.21. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Rigel Pharmaceuticals is now worth
$ 143.45
Giving a profit of
$ 43.45 (43.45%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
50%
Hold
50%
Sell
0%
Markets Today
Today's Change
+$1.24 (+2.78%)
Day High
$46.21
Day Low
$43.44
Day Open
$44.21
Prev Close
$44.52
Volume
2,03,335
1W Return
-10.85%
1M Return
-6.39%
3M Return
8.93%
6M Return
74.65%
1Y Return
20.58%
Fundamentals
Market Cap ($ Mn)
862
PE Ratio
2.76
PB Ratio
2.04
PEG Ratio
0.01
ROE
299.43%
ROCE
70.28%
EPS (TTM)
$0.70
Investment Returns
1 Week
-10.85%
1 Month
-6.39%
3 Months
8.93%
6 Months
74.65%
9 Months
30.96%
Financials
Quarterly
All values in $ Mn
53.3
Mar 25
101.7
Jun 25
69.5
Sep 25
69.8
Dec 25
78.7
Jun 26
80.9
Sep 26
Updates
9Nov
Citigroup raises Rigel Pharmaceuticals price target to $86, keeps buy
Citigroup maintains Buy rating on Rigel Pharmaceuticals. Price target raised from $83 to $86 by analyst Yigal Nochomovitz. Rating action indicates sustained positive outlook on the stock.
3 days ago
6Nov
Cantor Fitzgerald lifts Rigel Pharmaceuticals price target to $47
Cantor Fitzgerald raised Rigel Pharmaceuticals' price target from $43 to $47. Analyst Kristen Kluska maintained a Neutral rating on the stock. The adjustment reflects an updated valuation perspective without changing the investment stance.
6 days ago
6Nov
Rigel Pharmaceuticals Q3FY26 Results: Net product sales up 13% YoY to $72.3M
Net product sales rose 13% YoY to $72.3 million in Q3FY26. New product Vepanu contributed $6.6 million in its first six weeks. FY26 revenue guidance narrowed to $290-$295 million from $285-$295 million. Tavalisse sales grew 3% to $46 million; Rezlidhia rose 20% to $9.9 million. Guidance remains below analyst consensus estimate of $305.733 million.
7 days ago
4Nov
Rigel to present R289 Phase 1b data for MDS at ASH 2026
R289 Phase 1b oral presentation scheduled for Dec 12, 2026, at ASH. Study enrolled 64 patients; 81.6% response rate seen in ITP combo subgroup. Three TAVALISSE posters to highlight real-world data in ITP and wAIHA. No new safety signals detected in Japan post-marketing surveillance.
8 days ago
2Oct
Rigel Pharmaceuticals grants 35,275 RSUs to new employees
Granted 35,275 restricted stock units to 18 non-executive employees. Awards issued under the Inducement Plan per NASDAQ Listing Rule 5635(c)(4). RSUs vest over four years with 25% annual vesting. Grants serve as inducement material for new hires.
1mo ago
2Sep
Rigel CFO to present at three September investor conferences
Rigel CFO Dean Schorno will attend three investor conferences in New York this September. Presentations are scheduled at Citi, Cantor, and H.C. Wainwright events between Sept 9 and Sept 15. Live webcasts of Cantor and H.C. Wainwright sessions will be hosted on the company website.
